Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maine To Resubmit Medicaid Waiver To HHS After Court Strikes Plan Down

Executive Summary

Maine plans to seek approval for the "Healthy Maine" Prescription Drug Discount Program following a decision by the D.C. federal appeals court that the program was not approved by HHS

You may also be interested in...



Michigan Medicaid Gives Preferred Status To SSRIs, Atypical Antipsychotics

Michigan Medicaid's Rx prior authorization/ supplemental rebate program awards preferred status for drugs in the selective serotonin reuptake inhibitor and atypical antipsychotic classes

Michigan Medicaid Gives Preferred Status To SSRIs, Atypical Antipsychotics

Michigan Medicaid's Rx prior authorization/ supplemental rebate program awards preferred status for drugs in the selective serotonin reuptake inhibitor and atypical antipsychotic classes

Maine Rx Assistance Program Seeks To Reaffirm Rebates; Most Firms Re-Sign

Maine is seeking to relaunch its Low Cost Drugs for the Elderly and Disabled Program (DEL) by renewing rebate pledges from manufacturers

Related Content

UsernamePublicRestriction

Register

PS041055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel